2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: A novel class of MT 2-selective melatonin receptor antagonists

Journal of Medicinal Chemistry

Volumn 52, Issue 3, 2009, Pages 826-833

  Zlotos, Darius P ^a   Attia, Mohamed I ^a   Julius, Justin ^b   Sethi, Shalini ^b   Witt Enderby, Paula A ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2,3 DIHYDRO 1H INDOL 1 YL)METHYL]MELATONIN DERIVATIVE; ACETAMIDE DERIVATIVE; CYCLIC AMP; CYCLOBUTANECARBOXAMIDE; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; PARTIAL AGONIST; UNCLASSIFIED DRUG; DRUG DERIVATIVE; INDOLE DERIVATIVE; MELATONIN; MELATONIN RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR MODEL; NONHUMAN; RECEPTOR AFFINITY; STEREOCHEMISTRY; ANIMAL; CHO CELL; CRICETULUS; DRUG ANTAGONISM; DRUG POTENTIATION; HAMSTER; SYNTHESIS;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; INDOLES; MELATONIN; RECEPTORS, MELATONIN;

EID: 61449191838     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800974d     Document Type: Article

References (52)

1. Barrenetxe, J.; Delagrange, P.; Martinez, J. A. Physiological and metabolic functions of melatonin. J. Physiol. Biochem. 2004, 60, 61-72.
2. Pevet, P.; Bothorel, B.; Slotten, H.; Saboureau, M. The chronobiotic properties of melatonin. Cell Tissue Res. 2002, 309, 183-191.
3. Genovese, T.; Mazzon, E.; Muia, C.; Bramanti, P.; De Sarro, A.; Cuzzocrea, S. Attenuation in the evolution of experimental spinal cord trauma by treatment with melatonin. J. Pineal Res. 2005, 38, 198-208.
4. Peres, M. F. P. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005, 25, 403-111.
5. Iuvone, P. M.; Tosini, G.; Pozdeyev, N.; Haque, R.; Klein, D. C.; Chaurasia, S. S. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog. Retinal Eye Res. 2005, 24, 433-156.
6. Sewerynek, E. Melatonin and the cardiovascular system. Neuroendo - crinol. Lett. 2002, 23 (S.1), 79-83.
7. (a) Witt-Enderby, P. A.; Radio, N. M.; Doctor, J. S.; Davis, V. L. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J. Pineal Res. 2006, 41, 297-305.
8. (b) Blask, D. E.; Sauer, L. A.; Dauchy, R. T. Melatonin as a chronobiotic/ anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem. 2002, 2, 113-132.
9. (c) Mills, E.; Wu, P.; Seely, D.; Guyatt, G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J. Pineal Res. 2005, 39, 360-366.
10. Sofic, E.; Rimpapa, Z.; Kundurovic, Z.; Sapcanin, A.; Tahirovic, I.; Rustembegovic, A.; Cao, G. Antioxidant capacity of the neurohormone melatonin. J. Neural Transm. 2005, 112, 349-358.
11. Macleod, M. R.; O'Collins, T.; Horky, L. L.; Howells, D. W.; Donnan, G. A. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J. Pineal Res. 2005, 38, 35-41.
12. (a) Srinivasan, V.; Pandi-Perumal, S.; Cardinali, D.; Poeggeler, B.; Hardeland, R. Melatonin in Alzheimer's disease and other neurode - generative disorders. Behav. Brain Funct. 2006, 2, 15.
13. (b) Medeiros, C. A.; Carvalhedo de Bruin, P. F.; Lopes, L. A.; Magalhaes, M. C.; de Lourdes Seabra, M.; de Bruin, V. M. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. J. Neurol. 2007, 254, 459-464.
14. (a) Reppert, S. M.; Weaver, D. R.; Godson, C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci. 1996, 17, 100-102.
15. (b) Dubocovich, M. L.; Cardinali, D. P.; Delagrange, P.; Krause, D. N.; Strosberg, A. D.; Sugden, D.; Yocca, F. D. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd ed.; Girdlestone, D., Ed.; IUPHAR Media: London, 2000; pp 271-277.
16. Li, P.-K.; Witt-Enderby, P. A. Melatonin receptors as potential targets for drug discovery. Drugs Future 2000, 25, 945-957.
17. 2 melatonin receptor antagonists block melatonin - mediated phase advances of circadian rhythms. FASEB J. 1998, 12,1211-1220.
18. Liu, C.; Weaver, D. R.; Jin, X.; Shearman, L. P.; Pieschl, R. L.; Gribkoff, V. K.; Reppert, S. M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997, 19, 91-102.
19. Doolen, S.; Krause, D. N.; Dubocovich, M. L.; Duckles, S. P. Melatonin mediates two distinct responses in vascular smooth muscle. Eur. J. Pharmacol. 1998, 345, 67-69.
20. Hunt, A. E.; Al-Ghoul, W. M.; Gillette, M. U.; Dubocovich, M. L. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol. 2001, 280, C110-C118.
21. Dubocovich, M. L.; Markowska, M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27, 101-110.
22. (a) Zlotos, D. P. Recent advances in melatonin receptor ligands. Arch. Pharm. Chem. Life Sci. 2005, 338, 229-247.
23. (b) Garret, P. J.; Tsotinis, A. Synthesis of compounds as melatonin agonists and antagonists. Mini-Rev. Med. Chem. 2007, 7, 1075-1088.
24. Gershell, L. Insomnia market. Nat. Rev. Drug Discovery 2006, 5, 15-17.
25. Pandi-Perumal, S. R.; Srinivasan, V.; Poeggeler, B.; Hardeland, R.; Cardinali, D. P. Drug insight: the use of melatonergic agonists for the treatment of insomnia. Focus on ramelteon. Nat. Clin. Pract. Neurol. 2007, 3, 221-228.
26. Zemlan, F. P.; Mulchahey, J. J.; Scharf, M. B.; Mayleben, D. W.; Rosenberg, R.; Lankford, A. The efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J. Clin. Psychiatry 2005, 66, 384-390.
27. Rajaratnam, S. M. W.; Polymeropoulos, M. H.; Fisher, D. M.; Roth, T.; Scott, C.; Birznieks, G.; Klerman, E. B. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials Lancet 2008, doi: 10.1016/ S0140-6736(08)61812- 7.
28. Dubocovich, M. L. Agomelatine targets a range of major depressive disorder symptoms. Curr. Opin. Invest. Drugs 2006, 7, 670-80.
29. 1 melatonin receptors. J. Pineal Res. 2005, 39, 170-177.
30. (b) Tsotinios, A.; Afroudikas, P. A. Melatonin receptor antagonist luzindole: a facile new synthesis. Lett. Org. Chem. 2008, 5, 507-509.
31. Li, X. M.; Beau, J.; Delagrange, P.; Mocaer, E.; Levi, F. Circadian rhythm entrainment with melatonin, melatonin receptor antagonist S22153 or their combination in mice exposed to constant light. J. Pineal Res. 2004, 37, 176-184.
32. Willis, G. L. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. Drug News Perspect. 2005, 18, 437-444.
33. Spadoni, G.; Bedini, A. Advances on the Development of Subtype Selective Melatonin Ligands. In Melatonin: From Molecules to Therapy; Pandi-Perumal, S. R., Cardinali, D. P., Eds.; Nova Science Publishers, Inc.: Hauppauge, NY, 2007; pp 33-45.
34. 2 selective melatonin receptor antagonists: design and structure - activity relationships. ARKIVOC 2006, VIII,8-16.
35. 2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 553-561.
36. Yous, S.; Durieux-Poissonnier, S.; Lipka-Belloli, E.; Guelzim, H.; Bochu, C.; Audinot, V.; Boutin, J. A.; Delagrange, P.; Bennejean, C.; Renard, P.; Lesieur, D. Design and synthesis of 3-phenyl tetrahy - dronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Bioorg. Med. Chem. 2003, 11, 753-759.
37. 2 melatonin receptor selective ligands. J. Med. Chem. 2002, 45, 2788-2800.
38. Faust, R.; Garratt, P. J.; Jones, R.; Yeh, L.-K.; Tsotinis, A.; Panous-sopoulou, M.; Calogeropoulou, T.; Teh, M.-T.; Sugden, D. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a] isoquino - lines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a] indoles. J. Med. Chem. 2000, 43, 1050-1061.
39. 2 - selective melatonin antagonists. J. Med. Chem. 2001, 44, 2900-2912.
40. Lucini, V.; Pannacci, M.; Scaglione, F.; Fraschini, F.; Rivara, S.; Mor, M.; Bordi, F.; Plazzi, P. V.; Spadoni, G.; Bedini, A.; Piersanti, G.; Diamantini, G.; Tarzia, G. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. J. Med. Chem. 2004, 47, 4202-4212.
41. 2-selective melatonin receptor ligands. J. Med. Chem. 2006, 49, 7393-7403.
42. Rivara, S.; Lodola, A.; Mor, M.; Bedini, A.; Spadoni, G.; Lucini, V.; Pannacci, M.; Fraschini, F.; Scaglione, F.; Sanchez, R. O.; Gobbi, G.; Tarzia, G. N-(Substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J. Med. Chem. 2007, 50, 6618-6626.
43. 2 receptor models. J. Med. Chem. 2005, 48, 4049-060.
44. Attia, M. I.; Julius, J.; Witt-Enderby, P. A.; Zlotos, D. P. Synthesis and pharmacological evaluation of 6a,7-dihydro-6H,13H-pyrazino[1,2 - a;4,5-a']diindole analogs as melatonin receptor ligands. Tetrahedron 2007, 63, 754-760.
45. Attia, M. I.; Witt-Enderby, P. A.; Julius, J. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3 - dihydrodiindole derivatives as novel melatoninergic ligands. Bioorg. Med. Chem. 2008, 16, 7654-7661.
46. Gangjee, A.; Vasudevan, A.; Queener, S. F. Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methoxypyrido[2,3-d]pyri - midines with novel side chain substituents as potential inhibitors of dihydrofolate reductases. J. Med. Chem. 1997, 40, 479-485.
47. Attia, M. I.; Guclu, D.; Hertlein, B.; Julius, J.; Witt-Enderby, P. A.; Zlotos, D. P. Synthesis, NMR conformational analysis and pharmacological evaluation of 7,7a,13,14-tetrahydro-6H-cyclobuta[b]pyrim - ido[1,2-a:3,4-a']diindole analogues as melatonin receptor ligands. Org. Biomol. Chem. 2007, 5, 2129-2137.
48. Takami, M.; Okada, M.; Tsujii, S.; Hosogai, T.; Omura, S.; Adachi, A.; Yamada, Y. Indole Derivatives as Fungicides. JP 60149502, 1985.
49. Witt-Enderby, P. A.; Dubocovich, M. Characterization and regulation of the human ML1A melatonin receptor in CHO cells. Mol. Pharmacol. 1996, 50, 166-174.
50. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
51. Pcmodel, version 9.0; Serena Software (Box 3076, Bloomington, IN47402-3076).
52. HyperChem, version 7.1; Hyper Cube (1115 NW 4th Street, Gainesville, FL 32606).